White label ELPA - ClinicalTrials.eu

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Recruiting

3 1
Investigated Diseases:
- Systemic lupus erythematosus
+4
Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Recruiting

2 1
Investigated Diseases:
- Colitis ulcerative
+5
Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Recruiting

3 1
Investigated Diseases:
+4
Safety of flecainide acetate compared with amiodarone hydrochloride and sotalol in patients with atrial fibrillation and stable coronary artery disease

Recruiting

3 1 1 1
Investigated Drugs:
Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

Recruiting

3 1 1 1
Investigated Drugs:
Study of REGN7508 versus apixaban for treating and preventing cancer-associated blood clots in adults with solid or blood cancers

Recruiting

3 1 1 1
Investigated Diseases:
- Embolism
Investigated Drugs:
- Apixaban
- Regn7508
Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

Recruiting

3 1 1
Investigated Diseases:
- Multiple sclerosis
Investigated Drugs:
- Ocrelizumab
Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

Recruiting

3 1 1
Investigated Drugs:
- Azetukalner
Bempedoic acid in drug combination for patients with coronary artery disease without prior cardiovascular events

Recruiting

3 1 1 1
Investigated Diseases:
- Arteriosclerosis coronary artery
Investigated Drugs:
Open‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer

Recruiting

2 1 1
Investigated Diseases:
- Ovarian cancer
Investigated Drugs:
- Avutometinib
- Defactinib

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies